Brown Convention Center - Exhibit Halls A B About Werewolf Therapeutics Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today ...

Presentation Title: Development of a Surface Engineered Lentiviral Vector for In Vivo Generation of CD22-Directed CAR T Cells Presenting Author: Jeffrey Teoh, Ph.D. Poster Number: 1145 Presentation ...

Brown Convention Center A copy of the presentation materials will be added to the “ Publications ” section of the Company’s website at tscan.com once presentations have concluded. About TScan ...

Date: November 9, 2024 Poster Number: 226 Title: An effective donor screening program for manufacturing of allogeneic γδ T cell products Presenter: Inbar Azoulay Alfaguter, Ph.D. (Immatics) ...

Poster presentation details: Title: Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity ...

Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment ...

Pankaj Mohan, Founder and Chief Executive Officer of Sonnet commented, “We are grateful for NJEDA's continued support of the biotechnology industry and to be one of the recipients to benefit from the ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two ...

Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of ...

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...